Effects of Supplementary Oxygen on Dyspnoea and Exercise Tolerance in COPD Patients Given LTOT

This study has been completed.
Sponsor:
Collaborator:
The norwegian association for heart and lung patients
Information provided by:
LHL Helse
ClinicalTrials.gov Identifier:
NCT00249093
First received: November 4, 2005
Last updated: April 12, 2007
Last verified: April 2007
  Purpose

The aim of the study is to evaluate effects of supplementary oxygen during exercise on dyspnoea and exercise tolerance in COPD-patients given long-time oxygen treatment


Condition Intervention
COPD
Drug: oxygen

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind
Primary Purpose: Diagnostic

Resource links provided by NLM:


Further study details as provided by LHL Helse:

Primary Outcome Measures:
  • dyspnea
  • exercise tolerance

Estimated Enrollment: 20
Study Start Date: October 2005
Study Completion Date: April 2007
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • COPD patients (male/female)given long-term oxygen treatment
  • Able to perform two separate walking tests

Exclusion Criteria:

  • Severe heart failure
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00249093

Locations
Norway
Glittreklinikken
Hakadal, Norway, 1485
Sponsors and Collaborators
LHL Helse
The norwegian association for heart and lung patients
Investigators
Principal Investigator: Morten S Ryg, dr philos LHL Helse
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00249093     History of Changes
Other Study ID Numbers: G25-1
Study First Received: November 4, 2005
Last Updated: April 12, 2007
Health Authority: Norway:National Committee for Medical and Health Research Ethics

Additional relevant MeSH terms:
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on April 17, 2014